Currently, systematic (intraperitoneal) administration of CXCR4 antagonist, AMD3100, was demonstrated to have analgesic effects on opioid-induced hyperalgesia [8] and neuropathic pain induced by peripheral neuropathy [3] and by anti-AIDS therapy [6], [7]. The gene discussed is CXCR4; the disease is peripheral neuropathy.